Aravive, Inc. (ARAV) stock rallied over 8.61% intraday to trade at $1 a share on NASDAQ. The stock opened with a gain of 9.89% at $0.92 and touched an intraday high of $1.06, rising 8.58% against the last close of $0.921. The stock went to a low of $0.92 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue8.28 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Aravive, Inc. (NASDAQ: ARAV) stock price is $1 as of the last check on Monday, August 8. During the trading session, ARAV stock reached the peak price of $1.06 while $0.92 was the lowest point it dropped to.
The NASDAQ listed ARAV is part of Biotechnology industry that operates in the broader Health Care sector. Aravive, Inc. , a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States.
Dr. Fredric N. Eshelman Pharm.D.
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.
Pres, CEO & Director
Dr. Joshua Silverman Ph.D.
Mr. Rudy C. Howard B.A., CPA, CPA
Chief Financial Officer
ARAV stock traded closed the last session at $1, which is $0.07930000000000004 or 8.613011838818295% lower than its previous close of $0.921. ARAV's current trading price is 25.69% lower than its 52-week high of $4.4 where as its distance from 52-week low of 0.8% is -77.27%.
Number of ARAV employees currently stands at -. ARAV operates from River Oaks Tower, Suite 1200 3730 Kirby Drive, Houston, TX 77098, United States.
Official Webiste of $ARAV is: https://aravive.com
ARAV stock volume for the day was 232,887 shares while in the previous session number of ARAV shares traded was 232,887 . The average number of ARAV shares traded daily for last 3 months was 91.42 Thousands.
The percentage change in ARAV stock occurred in the recent session was 8.613011838818295% while the dollar amount for the price change in ARAV stock was $0.07930000000000004.
In the recent session, the day high for ARAV stock was $1.06 while the low for ARAV stock touched on the day was $0.92.
The market value of ARAV currently stands at 28.45 Million with its latest stock price at $1 and 21.13 Million of its shares outstanding.